Article Details

Sarepta's muscular dystrophy therapy fails to meet main goal in late-stage trial | Reuters

Retrieved on: 2023-10-30 21:52:01

Tags for this article:

Click the tags to see associated articles and topics

Sarepta's muscular dystrophy therapy fails to meet main goal in late-stage trial | Reuters. View article details on hiswai:

Excerpt

Roche Holding AG. Follow. Oct 30 (Reuters) - Sarepta Therapeutics' (SRPT.O) gene therapy to treat Duchenne muscular dystrophy (DMD), a progressive ...

Article found on: www.reuters.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up